LUBAC facilitates somatic mutations in genes frequently mutated in human DLBCL. (A-C) Mutations with VAF >0.05 in tumor samples were selected and analyzed. (A) Numbers of total mutations including both synonymous and nonsynonymous mutations in each tumor sample. Boxes represent the median and the first and third quartiles, and whiskers represent the minimum and maximum of all data points. (B) Venn diagram depicting the overlap between genes recurrently mutated nonsynonymously in lymphoma cells derived from CD19-cre-HOIP/MYD88LP mice and those frequently detected in human DLBCL.³⁰  (C) Mutational heatmap showing recurrently mutated genes across sequenced samples, color-coded according to 5 types of genetic alteration. Above the mutational heatmap, the bar graph indicates the number of nonsynonymous mutations in each sample. To the right of the mutational heatmap, the stacked bar graph indicates the percentage of tumors that have each mutations, using the same 5-color scheme. Target genes of aberrant somatic hypermutation induced by AID in human DLBCL are labeled in red. Black daggers indicates murine homologous genes frequently mutated in human DLBCL.³⁰  Red and blue daggers indicate murine homolog of previously reported altered genes significantly enriched in human ABC-DLBCL and GCB-DLBCL, respectively.³⁰  ***P < .001, Brunner-Munzel test (A). (B) Fisher’s exact test. See also supplemental Figure 3 and supplemental Table 5.